# Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

> **NCT01207765** · PHASE2 · TERMINATED · sponsor: **Tufts Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** indium-111-ibritumomab tiuxetan
- **DRUG:** 90Y Zevalin

## Key facts

- **NCT ID:** NCT01207765
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2013-01
- **Final completion:** 2013-06
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** changes in practice
- **Last updated:** 2017-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01207765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01207765, "Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01207765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*